The diabetic treatment ‘Janumet XR’ exceeded the annual sales of KRW 10 billion within a year
The MSD Korea’s (CEO Dong-wook Hyun) DDP-4 inhibitor, the sitagliptin/metformin extended release ‘Janumet XR’, recorded the annual sales of KRW 10.3 billion (based on the UBIST’s outpatient prescription expenses) in 2014.
Along with the prescription raise with Janumet XR, the market of DDP-4 inh...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
